The International Collaboration on Cosmetics Safety enters a new chapter with the appointment of its 2026 Board officers, reinforcing its global commitment to advancing animal-free approaches in cosmetics safety science at a time of rapid regulatory and scientific change.
The International Collaboration on Cosmetics Safety (ICCS) has announced its confirmed Board officers for 2026, following elections conducted during the organization’s December 2025 Board meeting, marking a notable achievement for the still young global initiative as it advances its role in promoting scientifically sound, human‑relevant alternatives to animal testing in cosmetics safety evaluation, with the newly appointed leadership illustrating both continuity and the increasing sophistication of ICCS as it builds on a year of meaningful advancements and prepares to broaden its influence across regulatory, scientific, and industry spheres worldwide.
ICCS operates at the intersection of science, policy, and collective engagement, bringing together a wide spectrum of stakeholders who pursue a common goal: promoting the global acceptance and implementation of animal-free safety science for cosmetics and their ingredients. The designation of the 2026 Board officers underscores the organization’s dedication to maintaining a strategic direction while adapting to an increasingly complex international landscape, where expectations related to ethical research, scientific rigor, and regulatory alignment continue to evolve.
Ongoing leadership stability and worldwide representation
The 2026 Board leadership brings together senior figures from the cosmetics, consumer goods, and regulatory advocacy sectors, emphasizing the multi‑stakeholder framework that has defined ICCS since its inception. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been reappointed as Chair of the Board of Directors. His continued term signals enduring confidence in a leadership approach grounded in scientific rigor, cross‑border cooperation, and constructive engagement with regulatory authorities.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose experience in industry representation and regulatory dialogue adds a valuable regional and policy-oriented perspective. The role of Secretary will be held by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing deep expertise in regulatory toxicology and global product safety frameworks. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been elected Treasurer, contributing extensive experience in toxicology leadership and governance.
Together, the officers constitute a leadership team whose background extends across multinational corporations, industry groups, and regulatory science, thereby strengthening ICCS’ role as a neutral forum for collaboration rather than a promoter of any individual sector. This equilibrium remains essential to the organization’s credibility, especially as it aims to shape regulatory perspectives and foster alignment on animal-free safety approaches.
Advancing animal-free science through collaboration
ICCS’ mission is grounded in the belief that animal-free safety assessment methods, once thoroughly optimized and validated, are not only ethically responsible but also capable of delivering exceptional scientific outcomes. Since its founding in early 2023, ICCS has worked to demonstrate that non-animal approaches can produce reliable, relevant data that protect both human health and the environment. The confirmation of the 2026 Board officers comes at a moment when this message is gaining strength, supported by tangible progress and growing involvement from regulators worldwide.
During 2025, ICCS delivered a series of initiatives that strengthened its scientific foundation and expanded its influence. Among these was the release of a Best Practice Guidance document, designed to provide clarity and consistency in the application of animal-free safety assessment approaches. This guidance aimed to bridge gaps between scientific innovation and regulatory expectations, offering a practical framework that stakeholders could reference when developing or evaluating non-animal data.
In parallel, ICCS supported the development of new methodologies aligned with next generation risk assessment (NGRA), an evolving paradigm that integrates advanced in vitro, in silico, and exposure-based approaches. These methodologies are increasingly viewed as essential to modern toxicology, offering the potential for more human-relevant insights while reducing reliance on animal testing. ICCS’ involvement in this space reflects its commitment to advancing not only ethical outcomes but also scientific excellence.
ICCS has also placed strong importance on open dialogue, and throughout 2025 the organization engaged widely with regulators, scientists, and policymakers in various regions, helping shape conversations about how animal-free data can be interpreted and integrated into current regulatory systems, a series of exchanges that has significantly advanced mutual understanding and confidence, especially in regions where the approval of non-animal approaches is still evolving.
A decisive turning point in cosmetics safety oversight
The installation of the 2026 Board officers takes place during a phase marked by notable transformations in global cosmetics regulations, as many markets reassess long‑standing testing standards in response to public expectations, scientific advancements, and new international policy trends, and within this shifting environment, organizations like ICCS remain vital in aligning innovation with regulatory requirements to ensure that progress continues to be both reliable and sustainable.
ICCS leadership has long underscored that moving toward animal‑free safety science cannot progress through isolated initiatives; rather, it demands synchronized engagement from industry, academia, regulatory bodies, and civil society. The Board’s makeup embodies this principle by uniting figures who grasp the technical, regulatory, and organizational aspects required to drive meaningful transformation.
Statements from ICCS leadership following the elections highlighted both confidence and realism. While there is recognition of the momentum generated in recent years, there is also acknowledgment that significant work remains. Achieving widespread regulatory acceptance of animal-free approaches will require continued investment in research, transparent data sharing, and ongoing engagement with authorities to address legitimate questions around reliability, applicability, and protection of public health.
The re-elected Chair emphasized the vital need to rely on ICCS’ global, multi-stakeholder framework to close the gap between innovation and regulation, ensuring that advances in animal-free science extend beyond the laboratory and evolve into dependable, consistently implemented tools that regulators can trust.
Strengthening the foundation for enduring influence
As ICCS moves toward 2026 and the years that follow, the organization aims to reinforce its progress while broadening its influence, and the newly appointed Board leadership is anticipated to guide key priorities that balance scientific aspirations with practical execution, including pinpointing topics that require further direction or consensus, backing the validation and dissemination of emerging methodologies, and promoting global harmonization to minimize fragmentation among regulatory expectations.
Education remains another key pillar of ICCS’ strategy. By providing accessible, science-based resources and forums for discussion, the organization aims to demystify animal-free safety science and encourage informed decision-making. This is particularly important in a field where misconceptions or uneven understanding can slow progress, even when the underlying science is sound.
The organization’s structure, which includes market-leading cosmetics and ingredient manufacturers, trade and research associations, and animal protection organizations, positions it uniquely to address these challenges. This diversity of perspectives helps ensure that discussions remain grounded, balanced, and focused on shared goals rather than narrow interests.
Based in New York, ICCS remains active as a global initiative that underscores the inherently international landscape of cosmetics research and regulation. As products and ingredients frequently cross national borders, aligning standards and encouraging mutual acceptance of safety practices become ever more crucial. By working collaboratively, ICCS aims to support this alignment, minimize redundant efforts, and strengthen confidence in animal-free science around the world.
In confirming its 2026 Board officers, ICCS signals both stability and forward momentum. The leadership team brings continuity from a year marked by concrete achievements, alongside the experience and perspective needed to navigate the next phase of change. As scientific innovation accelerates and regulatory expectations evolve, the organization’s role as a convener and catalyst for animal-free cosmetics safety science is set to become even more relevant.
Ultimately, the significance of the 2026 Board elections arises not only from who is chosen but also from the message their leadership sends: a sustained commitment to collaboration, scientific rigor, and the careful advancement of alternatives to animal testing. For ICCS and its stakeholders, the coming years offer an opportunity to convert vision into lasting outcomes, guiding the future of cosmetics safety in a way that unites ethics, science, and global public trust.
